Standardizing the definition of adverse pathology for lower risk men undergoing radical prostatectomy
详细信息 查看全文
- 作者：Michael A. Kozminski ; M.D.a ; Scott Tomlins ; M.D. ; Ph.D.b ; Adam Colea ; Udit Singhala ; Louis Lua ; Ted A. Skolarus ; M.D.a ; d ; Ganesh S. Palapattu ; M.D.a ; Jeffrey S. Montgomery ; M.D. ; M.S.a ; Alon Z. Weizer ; M.D.a ; Rohit Mehra ; M.B.B.S.b ; Brent K. Hollenbeck ; M.D.a ; David C. Miller ; M.D.a ; Chang Hea ; Felix Y. Feng ; M.D.c ; Todd M. Morgan ; M.D.a ; tomorgan@med.umich.edu" class="auth_mail" title="E-mail the corresponding author
- 关键词：Biochemical recurrence ; Biomarkers ; Prostate cancer
- 刊名：Urologic Oncology: Seminars and Original Investigations
- 出版年：2016
- 出版时间：September 2016
- 年：2016
- 卷：34
- 期：9
- 页码：415.e1-415.e6
- 全文大小：205 K
文摘
- •
Definitions of adverse pathology after prostatectomy vary in prognostic performance.
- •
Pathologic T3-4 or primary Gleason pattern 4 performs best in terms of BCR prediction.
- •
10% or less of men with lowest preop risk will have this adverse path at resection.